Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Eur J Endocrinol. 2022 Jun 24;187(2):257-263. doi: 10.1530/EJE-22-0206. Print 2022 Aug 1.
Successful preoperative image localisation of all parathyroid adenomas (PTA) in patients with primary hyperparathyroidism (pHPT) and multiglandular disease (MGD) remains challenging. We investigate whether a machine learning classifier (MLC) could predict the presence of overlooked PTA at preoperative localisation with 99mTc-Sestamibi-SPECT/CT in MGD patients.
This study is a retrospective study from a single tertiary referral hospital initially including 349 patients with biochemically confirmed pHPT and cured after surgical parathyroidectomy.
A classification ensemble of decision trees with Bayesian hyperparameter optimisation and five-fold cross-validation was trained with six predictor variables: the preoperative plasma concentrations of parathyroid hormone, total calcium and thyroid-stimulating hormone, the serum concentration of ionised calcium, the 24-h urine calcium and the histopathological weight of the localised PTA at imaging. Two response classes were defined: patients with single-gland disease (SGD) correctly localised at imaging and MGD patients in whom only one PTA was localised on imaging. The data set was split into 70% for training and 30% for testing. The MLC was also tested on a subset of the original data based on CT image-derived PTA weights.
The MLC achieved an overall accuracy at validation of 90% with an area under the cross-validation receiver operating characteristic curve of 0.9. On test data, the MLC reached a 72% true-positive prediction rate for MGD patients and a misclassification rate of 6% for SGD patients. Similar results were obtained in the testing set with image-derived PTA weight.
Artificial intelligence can aid in identifying patients with MGD for whom 99mTc-Sestamibi-SPECT/CT failed to visualise all PTAs.
在原发性甲状旁腺功能亢进症(pHPT)伴多腺体疾病(MGD)患者中,成功地对所有甲状旁腺腺瘤(PTA)进行术前影像学定位仍然具有挑战性。我们研究了机器学习分类器(MLC)是否可以预测在 MGD 患者中,术前 99mTc-Sestamibi-SPECT/CT 定位时是否存在被忽视的 PTA。
这是一项来自单一三级转诊医院的回顾性研究,最初纳入了 349 例经生化证实的 pHPT 患者,这些患者在手术后甲状旁腺切除术治愈。
使用具有贝叶斯超参数优化和五重交叉验证的决策树分类集成对 6 个预测变量进行训练:术前甲状旁腺激素、总钙和促甲状腺激素的血浆浓度、血清离子钙浓度、24 小时尿钙浓度和影像学定位的局部 PTA 的组织病理学重量。定义了两个响应类别:在影像学上正确定位的单腺体疾病(SGD)患者和在影像学上仅定位一个 PTA 的 MGD 患者。数据集分为 70%用于训练和 30%用于测试。还基于 CT 图像衍生的 PTA 权重对原始数据的一个子集进行了 MLC 测试。
在验证中,MLC 的总体准确率为 90%,交叉验证接收者操作特征曲线下的面积为 0.9。在测试数据中,MLC 对 MGD 患者的真阳性预测率为 72%,对 SGD 患者的误分类率为 6%。在基于图像衍生的 PTA 权重的测试集中也得到了类似的结果。
人工智能可以帮助识别出 99mTc-Sestamibi-SPECT/CT 未能显示所有 PTA 的 MGD 患者。